Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Mallinckrodt
AstraZeneca
Johnson and Johnson
Merck

Last Updated: May 25, 2022

Karyopharm Theraps Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for KARYOPHARM THERAPS, and what generic alternatives to KARYOPHARM THERAPS drugs are available?

KARYOPHARM THERAPS has one approved drug.

There are six US patents protecting KARYOPHARM THERAPS drugs.

There are one hundred patent family members on KARYOPHARM THERAPS drugs in thirty-six countries and eight supplementary protection certificates in eight countries.

Summary for Karyopharm Theraps
International Patents:100
US Patents:6
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Karyopharm Theraps

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No See Plans and Pricing See Plans and Pricing
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No 9,714,226 See Plans and Pricing Y Y See Plans and Pricing
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-003 Apr 15, 2021 RX Yes No 9,079,865 See Plans and Pricing See Plans and Pricing
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-003 Apr 15, 2021 RX Yes No 9,714,226 See Plans and Pricing Y Y See Plans and Pricing
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No 8,999,996 See Plans and Pricing Y Y See Plans and Pricing
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No See Plans and Pricing See Plans and Pricing
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No 10,544,108 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Karyopharm Theraps Drugs

Country Patent Number Estimated Expiration
European Patent Office 3180331 See Plans and Pricing
Australia 2021286266 See Plans and Pricing
Japan 2018111713 See Plans and Pricing
Lithuania 2736887 See Plans and Pricing
Georgia, Republic of P201706616 See Plans and Pricing
Canada 2842364 See Plans and Pricing
Australia 2012290454 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Karyopharm Theraps Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2736887 2021C/532 Belgium See Plans and Pricing PRODUCT NAME: SELINEXOR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1537 20210329
2736887 CA 2021 00031 Denmark See Plans and Pricing PRODUCT NAME: SELINEXOR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1537 20210329
2736887 301119 Netherlands See Plans and Pricing PRODUCT NAME: SELINEXOR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/21/1537 20210329
2736887 LUC00219 Luxembourg See Plans and Pricing PRODUCT NAME: SELINEXOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/21/1537 20210329
2736887 122021000055 Germany See Plans and Pricing PRODUCT NAME: SELINEXOR ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1537 20210326
2736887 29/2021 Austria See Plans and Pricing PRODUCT NAME: SELINEXOR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1537 (MITTEILUNG) 20210329
2736887 PA2021007 Lithuania See Plans and Pricing PRODUCT NAME: SELINEKSORAS; REGISTRATION NO/DATE: EU/1/21/1537 20210326
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Moodys
McKinsey
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.